RECHERCHE :   Cancers digestifs
Filtrage ? Le champ de filtrage permet de trier les études comportant le mot saisie. La recherche du mot se fait uniquement dans le contenu texte affiché à l'écran.
ETUDE PHASE SITE
AMGEN 20120139: A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical Trials
Tous les types de tumeurs
registre
CHUV
AMGEN 20140318 - T-VEC intrahepatic: A Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety of Talimogene Laherparepvec Injected into Liver Tumors Alone and in Combination With Systemic Pembrolizumab
Tumeur du foie non opérable (HCC) ou non-HCC
I, II
CHUV, HUG
BMS CA022-001: Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors
Tumeurs solides avancées
I, II
CHUV
INNOVATION: INtegratioN of trastuzumab, with or without pertuzumab, into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer
Cancer de l'estomac HER-2 positif
II
CHUV, HUG
KISIMA-01: An Open-Label, Multicenter, Non-Randomized, Dose-Confirmation and Cohort-Expansion Phase 1b Study to Evaluate the Safety, Tolerability, and Anti-Tumor Activity of ATP128, With or Without BI 754091, in Patients With Stage IV Colorectal Cancer
Stage IV colorectal cancer
I
HUG
MK1308A-004: Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma
Advanced hepatocellular carcinoma
II
HUG
MK3475-937: A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation
Hepatocellular carcinoma after surgical resection
III
CHUV, HUG
CO39612_MORPHEUS CRC: A phase Ib/II, open-label, multicenter, randomized umbrella study evaluating the efficacy and safety of multiple immunotherapy-based treatment combinations in patients with metastatic colorectal cancer.
Cancer coloréctal métastatique
I, II
CHUV
NAB-PIPAC: A phase IB trial of intraperitoneal cisplatin and Nab-Paclitaxel administered by pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the treatment of advanced malignancies confined to the peritoneal cavity
Peritoneal carcinomatosis from pancreatic, oesogastric, epithelial ovarian cancers or primitive peritoneal mesothelioma
I
HUG
CHUV-DO-0018-NeoTIL-2019: Pilot Study to Assess the Feasibility, Safety and Efficacy of Adoptive Transfer of Autologous Tumor-Infiltrating Lymphocytes Enriched for Tumor Antigen Specificity (NeoTIL) in Advanced Solid Tumors.
Tumeurs solides
I
CHUV
CHUV-DO-0011-PC_PEP-DC_2017: A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine and Standard Of Care Adjuvant Chemotherapy followed by Nivolumab for Resected Pancreatic Adenocarcinoma
Adénocarcinome du pancréas
I
CHUV
PEMREC:A Phase II Study to Evaluate Safety and Efficacy of Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer
Localised MSS Rectal Cancer
II
HUG
RACIN, A phase I study of the combination of nivolumab associated with low-dose radiation, aspirin/ celecoxib and either ipilimumab or low-dose cyclophosphamide, followed by nivolumab maintenance, in patients with advanced, TIL-negative solid tumors
Tumeurs solides
I
CHUV